Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-181 Phase 1 in Healthy Volunteers
NCT06286033Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AG-181 (4 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Adverse Events at 7 days, Serious Adverse Events at 7 days and 8 more. Started Feb 2024; status: completed.
02
Drugs
AG-181
Beyond the preview
Go deeper on NCT06286033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286033.